NO20005832L - Nye spesielle formuleringer - Google Patents

Nye spesielle formuleringer

Info

Publication number
NO20005832L
NO20005832L NO20005832A NO20005832A NO20005832L NO 20005832 L NO20005832 L NO 20005832L NO 20005832 A NO20005832 A NO 20005832A NO 20005832 A NO20005832 A NO 20005832A NO 20005832 L NO20005832 L NO 20005832L
Authority
NO
Norway
Prior art keywords
new special
special formulations
formulations
new
special
Prior art date
Application number
NO20005832A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005832D0 (no
Inventor
Walter Perkins
Xingong Li
Donald Hirsch
Eric Mayhew
Imran Ahmad
Shaukat Ali
Andrew S Janoff
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of NO20005832D0 publication Critical patent/NO20005832D0/no
Publication of NO20005832L publication Critical patent/NO20005832L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20005832A 1998-05-20 2000-11-17 Nye spesielle formuleringer NO20005832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8610898P 1998-05-20 1998-05-20
PCT/US1999/010975 WO1999059550A1 (en) 1998-05-20 1999-05-19 Novel particulate formulations

Publications (2)

Publication Number Publication Date
NO20005832D0 NO20005832D0 (no) 2000-11-17
NO20005832L true NO20005832L (no) 2001-01-18

Family

ID=22196324

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005832A NO20005832L (no) 1998-05-20 2000-11-17 Nye spesielle formuleringer

Country Status (18)

Country Link
US (1) US6500461B2 (ru)
EP (1) EP1079812A4 (ru)
JP (1) JP2002535242A (ru)
KR (1) KR20010052368A (ru)
CN (1) CN1310612A (ru)
AR (1) AR019308A1 (ru)
AU (1) AU745015B2 (ru)
BR (1) BR9911031A (ru)
CA (1) CA2332545A1 (ru)
EA (1) EA200001109A1 (ru)
EE (1) EE200000693A (ru)
ID (1) ID28166A (ru)
IL (1) IL139541A0 (ru)
NO (1) NO20005832L (ru)
PL (1) PL344327A1 (ru)
SK (1) SK17422000A3 (ru)
TR (1) TR200003435T2 (ru)
WO (1) WO1999059550A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
EP1781182B1 (en) 2004-07-08 2019-11-13 PneumRx, Inc. Pleural effusion treatment device
JP2008506780A (ja) 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク. 活性剤放出のための粒子状構築物
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
EP2176251B1 (en) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis IMAGING PARTICLES
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2674417A3 (en) 2007-11-21 2014-04-09 Decode Genetics EHF Biaryl PDE4 inhibitors for treating inflammation
CN101945872B (zh) 2008-01-11 2014-07-23 阿尔巴尼分子研究公司 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚
JP5539993B2 (ja) * 2008-09-23 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 薬物送達のためのナノ担体
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2010207486B2 (en) 2009-01-26 2013-03-07 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
CN101670095B (zh) * 2009-04-13 2012-05-23 北京大学 一种用于栓塞治疗的药物组合物及其制备方法
MX2012000572A (es) 2009-07-14 2012-05-08 Albany Molecular Res Inc Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.
AU2010339809B2 (en) 2009-12-17 2016-05-05 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
US9498439B2 (en) * 2010-04-15 2016-11-22 Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
WO1991019486A1 (en) * 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
NZ253999A (en) * 1992-08-05 1996-07-26 Faulding F H & Co Ltd Pelletised substained release medicament
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
KR100401220B1 (ko) * 1995-09-12 2004-03-20 더 리포좀 컴퍼니, 인코퍼레이티드 가수분해를촉진시키는소수성탁산유도체
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same

Also Published As

Publication number Publication date
EA200001109A1 (ru) 2001-06-25
WO1999059550A1 (en) 1999-11-25
AU745015B2 (en) 2002-03-07
CA2332545A1 (en) 1999-11-25
EE200000693A (et) 2002-04-15
NO20005832D0 (no) 2000-11-17
PL344327A1 (en) 2001-10-22
EP1079812A4 (en) 2001-12-12
KR20010052368A (ko) 2001-06-25
CN1310612A (zh) 2001-08-29
JP2002535242A (ja) 2002-10-22
AU4190699A (en) 1999-12-06
EP1079812A1 (en) 2001-03-07
SK17422000A3 (sk) 2001-09-11
US20020034536A1 (en) 2002-03-21
TR200003435T2 (tr) 2001-03-21
IL139541A0 (en) 2004-02-08
AR019308A1 (es) 2002-02-13
US6500461B2 (en) 2002-12-31
ID28166A (id) 2001-05-10
BR9911031A (pt) 2002-01-29

Similar Documents

Publication Publication Date Title
NO20005832L (no) Nye spesielle formuleringer
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO20021116L (no) Nye sammensetninger
PT1130966E (pt) Formulacoes antiparasitarias
ID23299A (id) Formulasi-formulasi farmasi
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
ATE227074T1 (de) Mikrokapsel-formulierungen
ID23287A (id) Trisiklik tersubstitusi
NO20020810L (no) Nye fenylpiperaziner
NO20015074L (no) Nye sammensetninger
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
NO20010860D0 (no) Nye forbindelser
ATE232683T1 (de) Mikrokapsel-formulierungen
NO20010861D0 (no) Nye forbindelser
ID23219A (id) Trisiklik tersubstitusi
NO20005857L (no) Nye blandinger
NO20010584L (no) Nye forbindelser
NO20011262D0 (no) Nye forbindelser
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
DE59911610D1 (de) Substituierte benzoylcyclohexandione

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application